Literature DB >> 20628843

Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA.

Wei Wu1, Dengfu Yao, Yilang Wang, Liwei Qiu, Wenli Sai, Junling Yang, Ninghua Yao, Shanshan Li, Yinzhu Bian, Zhiwei Wang, Dengbing Yao.   

Abstract

Nuclear factor-kappaB (NF-κB) is a transcription factor and antagonist of apoptosis during liver regeneration and closely related to the formation and development of hepatocellular carcinoma. In the present study, we investigated the effect of small interference RNA (siRNA)-mediated inhibition of NF-κB on growth of human hepatoma (HepG2) cells. Our data indicated that the expression of NF-κB/p65 mRNA was significantly higher in the HepG2 cells than that in the normal liver (LO2) cells before transfection, and the expression of NF-κB/p65 in the HepG2 cells with NF-κB/p65 siRNA (100 nMol/L) transfection at 72 h was reduced at the levels of mRNA (93%) and protein (62%) using real-time reverse transcription-polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blotting. Interestingly, the apoptosis index of the HepG2 cells increased up to 85%, detected by Annexin V-fluorescein isothiocyanate, suggesting that NF-κB is overexpressed in hepatoma cells and can be inhibited by NF-κB/p65 siRNA through the apoptotic mechanism. Thus, we conclude that NF-κB is a potential molecular target for HCC gene therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20628843     DOI: 10.1007/s13277-010-0076-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  36 in total

Review 1.  Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.

Authors:  Maddalena Frau; Fiorella Biasi; Francesco Feo; Rosa M Pascale
Journal:  Mol Aspects Med       Date:  2010-02-20

2.  Astragalus saponins induce apoptosis via an ERK-independent NF-kappaB signaling pathway in the human hepatocellular HepG2 cell line.

Authors:  Kathy Ka-wai Auyeung; Pui-ching Law; Joshua Ka-shun Ko
Journal:  Int J Mol Med       Date:  2009-02       Impact factor: 4.101

3.  Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas.

Authors:  Bert H O'Neil; Petra Bůzková; Hillary Farrah; David Kashatus; Hanna Sanoff; Richard M Goldberg; Albert S Baldwin; William K Funkhouser
Journal:  Oncology       Date:  2007-11-15       Impact factor: 2.935

Review 4.  Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma.

Authors:  Francesco Feo; Maddalena Frau; Maria L Tomasi; Stefania Brozzetti; Rosa M Pascale
Journal:  Exp Biol Med (Maywood)       Date:  2009-05-08

5.  Characteristics of hepatic nuclear-transcription factor-kappa B expression and quantitative analysis in rat hepatocarcinogenesis.

Authors:  Wei Wu; Deng-Fu Yao; Li-Wei Qiu; Wen-Li Sai; Jun-Jun Shen; Hong-Bo Yu; Xin-Hua Wu; Yue-Ming Li; Yi-Lang Wang; Wen-Jing Gu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2009-10

6.  Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.

Authors:  Keisuke Kohga; Tetsuo Takehara; Tomohide Tatsumi; Takuya Miyagi; Hisashi Ishida; Kazuyoshi Ohkawa; Tatsuya Kanto; Naoki Hiramatsu; Norio Hayashi
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

7.  Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor.

Authors:  Md Nasimuzzaman; Gulam Waris; David Mikolon; Dwayne G Stupack; Aleem Siddiqui
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

8.  High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer.

Authors:  Runqiu Jiang; Yongxiang Xia; Jun Li; Lei Deng; Liang Zhao; Jian Shi; Xuehao Wang; Beicheng Sun
Journal:  Int J Cancer       Date:  2010-03-01       Impact factor: 7.396

9.  Different expression of apoptotic proteins between HBV-infected and non-HBV-infected hepatocellular carcinoma.

Authors:  Chi-Sen Chang; Shen-Min Huang; Hui-Hsuan Lin; Cheng-Chung Wu; Chau-Jong Wang
Journal:  Hepatogastroenterology       Date:  2007 Oct-Nov

10.  IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C.

Authors:  Yongchao He; Hongwei Zhang; Jianhua Yin; Jiaxin Xie; Xiaojie Tan; Shijian Liu; Qian Zhang; Chengzhong Li; Jun Zhao; Hongyang Wang; Guangwen Cao
Journal:  Carcinogenesis       Date:  2009-10-01       Impact factor: 4.944

View more
  6 in total

1.  Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy.

Authors:  Min Yao; Li Wang; Zhizhen Dong; Qi Qian; Yun Shi; Dandan Yu; Shiye Wang; Wenjie Zheng; Dengfu Yao
Journal:  Tumour Biol       Date:  2014-03-16

2.  Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-κB gene transcription.

Authors:  Wei Wu; Jun-Ling Yang; Yi-Lang Wang; Han Wang; Min Yao; Li Wang; Juan-Juan Gu; Yin Cai; Yun Shi; Deng-Fu Yao
Journal:  World J Hepatol       Date:  2016-08-18

3.  Induced apoptosis in human prostate cancer cells by blocking of vascular endothelial growth factor by siRNA.

Authors:  A Deezagi; S Ansari-Majd; N Vaseli-Hagh
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

4.  Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I.

Authors:  Zhaowei Meng; Shanshan Lou; Jian Tan; Ke Xu; Qiang Jia; Wei Zheng
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

Review 5.  Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma.

Authors:  Min Yao; Li Wang; Yao Yao; Hong-Bing Gu; Deng-Fu Yao
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

6.  Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.

Authors:  Dandan Yu; Zhizhen Dong; Min Yao; Wei Wu; Meijuan Yan; Xiaodi Yan; Liwei Qiu; Jie Chen; Wenli Sai; Dengfu Yao
Journal:  Tumour Biol       Date:  2012-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.